Interferon regulatory factor-1 binds c-Cbl, enhances mitogen activated protein kinase signaling and promotes retinoic acid-induced differentiation of HL-60 human myelo-monoblastic leukemia cells

Leukemia and Lymphoma

Volumn 52, Issue 12, 2011, Pages 2372-2379

  Shen, Miaoqing ^a   Bunaciu, Rodica P ^a   Congleton, Johanna ^a   Jensen, Holly A ^a,b   Sayam, Lavanya G ^a   Varner, Jeffrey D ^b   Yen, Andrew ^a  

^a Department of Obstetrics Gynecology   (United States)

^b Cornell University   (United States)

Author keywords

C Cbl; Differentiation; HL 60; IRF 1; Neutrophil; RA

Indexed keywords

ALDEHYDE DEHYDROGENASE; AROMATIC HYDROCARBON RECEPTOR; CBL PROTEIN; CD38 ANTIGEN; INTERFERON REGULATORY FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; RETINOIC ACID;

ARTICLE; CANCER CELL; CELL CYCLE G0 PHASE; CELL DIFFERENTIATION; CELL STRAIN HL 60; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MYELOID LEUKEMIA; MYELOMONOCYTIC LEUKEMIA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RESPIRATORY BURST; SIGNAL TRANSDUCTION; STEM CELL;

ANTIGENS, CD38; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, LEUKEMIC; HL-60 CELLS; HUMANS; INTERFERON REGULATORY FACTOR-1; LEUKEMIA, MONOCYTIC, ACUTE; MAP KINASE SIGNALING SYSTEM; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-CBL; RECEPTORS, ARYL HYDROCARBON; TRETINOIN; UP-REGULATION;

EID: 82255196116     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.603449     Document Type: Article

References (66)

1. Yamada G, Ogawa M, Akagi K, et al. Specif c depletion of the B-cell population induced by aberrant expression of human interferon regulatory factor 1 gene in transgenic mice. Proc Natl Acad Sci USA 1991;88:532-536. (Pubitemid 21915499)
2. Tef eri A, Mathew P, Noel P. Te 5q-syndrome: a scientif c and clinical update. Leuk Lymphoma 1994;14:375-378.
3. Willman CL, Sever CE, Pallavicini MG, et al. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 1993;259:968-971. (Pubitemid 23080665)
4. Harada H, Kondo T, Ogawa S, et al. Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia; a possible mechanism of tumor suppressor inactivation. Oncogene 1994;9: 3313-3320.
5. Harada H, Willison K, Sakakibara J, et al. Absence of the type I IFN system in EC cells: transcriptional activator (IRF-1) and repressor (IRF-2) genes are developmentally regulated. Cell 1990;63:303-312.
6. Testa U, Stellacci E, Pelosi E, et al. Impaired myelopoiesis in mice devoid of interferon regulatory factor 1. Leukemia 2004;18:1864-1871. (Pubitemid 39530017)
7. Joshi S, Sharma B, Kaur S, et al. Essential role for Mnk kinases in type II interferon (IFNgamma) signaling and its suppressive effects on normal hematopoiesis. J Biol Chem 2011;286:6017-6026.
8. Waskiewicz AJ, Flynn A, Proud CG, et al. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 1997;16:1909-1920. (Pubitemid 27170952)
9. Yen A, Roberson MS, Varvayanis S, et al. Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell dif erentiation and growth arrest. Cancer Res 1998;58:3163-3172. (Pubitemid 28335101)
10. Hsu CY, Yung BY. Over-expression of nucleophosmin/B23 decreases the susceptibility of human leukemia HL-60 cells to retinoic acid-induced dif erentiation and apoptosis. Int J Cancer 2000;88: 392-400.
11. Pelicano L, Li F, Schindler C, et al. Retinoic acid enhances the expression of interferon-induced proteins: evidence for multiple mechanisms of action. Oncogene 1997;15:2349-2359. (Pubitemid 27496985)
12. Matikainen S, Ronni T, Hurme M, et al. Retinoic acid activates interferon regulatory factor-1 gene expression in myeloid cells. Blood 1996;88:114-123. (Pubitemid 26230678)
13. Matikainen S, Lehtonen A, Sareneva T, et al. Regulation of IRF and STAT gene expression by retinoic acid. Leuk Lymphoma 1998;30:63-71. (Pubitemid 28327256)
14. Alsayed Y, Modi S, Uddin S, et al. All-trans-retinoic acid induces tyrosine phosphorylation of the CrkL adapter in acute promyelocytic leukemia cells. Exp Hematol 2000;28:826-832. (Pubitemid 30411988)
15. Alsayed Y, Uddin S, Mahmud N, et al. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid. J Biol Chem 2001;276:4012-4019.
16. Kambhampati S, Li Y, Verma A, et al. Activation of protein kinase C delta by all-trans-retinoic acid. J Biol Chem 2003;278:32544-32551. (Pubitemid 37055692)
17. Kambhampati S, Verma A, Li Y, et al. Signalling pathways activated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Leuk Lymphoma 2004;45:2175-2185. (Pubitemid 39504311)
18. Kannan-Tulasiraman P, Dolniak B, Kaur S, et al. Role of the translational repressor 4E-BP1 in the regulation of p21(Waf1/Cip1) expression by retinoids. Biochem Biophys Res Commun 2008;368: 983-989.
19. Lal L, Li Y, Smith J, et al. Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 2005; 105:1669-1677. (Pubitemid 40223689)
20. Sassano A, Katsoulidis E, Antico G, et al. Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res 2007;67: 4524-4532. (Pubitemid 46815104)
21. Sassano A, Lo Iacono M, Antico G, et al. Regulation of leukemic cell dif erentiation and retinoid-induced gene expression by statins. Mol Cancer Ter 2009;8:615-625.
22. Schinke C, Goel S, Bhagat TD, et al. Design and synthesis of novel derivatives of all-trans retinoic acid demonstrate the combined importance of acid moiety and conjugated double bonds in its binding to PML-RAR-alpha oncogene in acute promyelocytic leukemia. Leuk Lymphoma 2010;51:1108-1114.
23. Vuletic A, Konjevic G, Milanovic D, et al. Antiproliferative effect of 13-cis-retinoic acid is associated with granulocyte dif erentiation and decrease in cyclin B1 and Bcl-2 protein levels in G0/G1 arrested HL-60 cells. Pathol Oncol Res 2010;16:393-401.
24. Giandomenico V, Vaccari G, Fiorucci G, et al. Apoptosis and growth inhibition of squamous carcinoma cells treated with interferon-alpha, IFN-beta and retinoic acid are associated with induction of the cyclin-dependent kinase inhibitor p21. Eur Cytokine Netw 1998;9:619-631. (Pubitemid 29033929)
25. Gaboli M, Gandini D, Delva L, et al. Acute promyelocytic leukemia as a model for cross-talk between interferon and retinoic acid pathways: from molecular biology to clinical applications. Leuk Lymphoma 1998;30:11-22. (Pubitemid 28327251)
26. Chelbi-Alix MK, Pelicano L. Retinoic acid and interferon signaling cross talk in normal and RA-resistant APL cells. Leukemia 1999;13:1167-1174. (Pubitemid 29396576)
27. Clarke N, Jimenez-Lara AM, Voltz E, et al. Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J 2004;23:3051-3060. (Pubitemid 39093599)
28. Garattini E, Mologni L, Ponzanelli I, et al. Cross-talk between retinoic acid and interferons: molecular mechanisms of interaction in acute promyelocytic leukemia cells. Leuk Lymphoma 1998;30: 467-475. (Pubitemid 28393681)
29. Hou X, Zhou R, Wei H, et al. NKG2D-retinoic acid early inducible-1 recognition between natural killer cells and Kupf er cells in a novel murine natural killer cell-dependent fulminant hepatitis. Hepatology 2009;49:940-949.
30. Kawaguchi S, Ishiguro Y, Imaizumi T, et al. Retinoic acid-inducible gene-I is constitutively expressed and involved in IFN-gamma-stimulated CXCL9-11 production in intestinal epithelial cells. Immunol Lett 2009;123:9-13.
31. Li K, Chen Z, Kato N, et al. Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes. J Biol Chem 2005;280:16739-16747. (Pubitemid 41389131)
32. Lou YJ, Pan XR, Jia PM, et al. IRF-9/STAT2 corrected functional interaction drives retinoic acid-induced gene G expression independently of STAT1. Cancer Res 2009;69:3673-3680.
33. Percario ZA, Giandomenico V, Fiorucci G, et al. Retinoic acid is able to induce interferon regulatory factor 1 in squamous carcinoma cells via a STAT-1 independent signalling pathway. Cell Growth Dif er 1999;10:263-270. (Pubitemid 29196662)
34. Vidal M, Ramana CV, Dusso AS. Stat1-vitamin D receptor interactions antagonize 1,25-dihydroxyvitamin D transcriptional activity and enhance stat1-mediated transcription. Mol Cell Biol 2002; 22:2777-2787. (Pubitemid 34262998)
35. Xiao S, Li D, Zhu HQ, et al. RIG-G as a key mediator of the antiproliferative activity of interferon-related pathways through enhancing p21 and p27 proteins. Proc Natl Acad Sci USA 2006;103: 16448-16453. (Pubitemid 44715216)
36. Shen M, Yen A. c-Cbl interacts with CD38 and promotes retinoic acid-induced dif erentiation and G0 arrest of human myeloblastic leukemia cells. Cancer Res 2008;68:8761-8769.
37. Bunaciu RP, Yen A. Activation of the aryl hydrocarbon receptor AhR promotes retinoic acid-induced dif erentiation of myeloblastic leukemia cells by restricting expression of the stem cell transcription factor Oct4. Cancer Res 2011;71:2371-2380.
38. Brooks SC 3rd, Kazmer S, Levin AA, et al. Myeloid dif erentiation and retinoblastoma phosphorylation changes in HL-60 cells induced by retinoic acid receptor-and retinoid X receptor-selective retinoic acid analogs. Blood 1996;87:227-237.
39. Wightman J, Roberson MS, Lamkin TJ, et al. Retinoic acid-induced growth arrest and dif erentiation: retinoic acid up-regulates CD32 (Fc gammaRII) expression, the ectopic expression of which retards the cell cycle. Mol Cancer Ter 2002;1:493-506.
40. Ginestier C, Hur MH, Charafe-Jaufret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555-567. (Pubitemid 350056407)
41. Bauvois B, Durant L, Laboureau J, et al. Upregulation of CD38 gene expression in leukemic B cells by interferon types I and II. J Interferon Cytokine Res 1999;19:1059-1066. (Pubitemid 29445064)
42. Tliba O, Damera G, Banerjee A, et al. Cytokines induce an early steroid resistance in airway smooth muscle cells: novel role of interferon regulatory factor-1. Am J Respir Cell Mol Biol 2008;38: 463-472. (Pubitemid 351758693)
43. Manzella L, Conte E, Cocchiaro G, et al. Role of interferon regulatory factor 1 in monocyte/macrophage dif erentiation. Eur J Immunol 1999;29:3009-3016. (Pubitemid 30099025)
44. Sanceau J, Kaisho T, Hirano T, et al. Triggering of the human interleukin-6 gene by interferon-gamma and tumor necrosis factor-alpha in monocytic cells involves cooperation between interferon regulatory factor-1, NF kappa B, and Sp1 transcription factors. J Biol Chem 1995;270:27920-27931.
45. Tamura T, Yanai H, Savitsky D, et al. Te IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 2008;26: 535-584. (Pubitemid 351600385)
46. Battistini A. Interferon regulatory factors in hematopoietic cell dif erentiation and immune regulation. J Interferon Cytokine Res 2009; 29:765-780.
47. Hess DA, Meyerrose TE, Wirthlin L, et al. Functional characterization of highly purif ed human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 2004;104:1648-1655. (Pubitemid 39202270)
48. Wang J, Yen A. A MAPK-positive feedback mechanism for BLR1 signaling propels retinoic acid-triggered dif erentiation and cell cycle arrest. J Biol Chem 2008;283:4375-4386.
49. Shen M, Yen A. c-Cbl tyrosine kinase-binding domain mutant G306E abolishes the interaction of c-Cbl with CD38 and fails to promote retinoic acid-induced cell dif erentiation and G0 arrest. J Biol Chem 2009;284:25664-25677.
50. Lamkin TJ, Chin V, Varvayanis S, et al. Retinoic acid-induced CD38 expression in HL-60 myeloblastic leukemia cells regulates cell dif erentiation or viability depending on expression levels. J Cell Biochem 2006;97:1328-1338.
51. Wu JP, Chang LW, Yao HT, et al. Involvement of oxidative stress and activation of aryl hydrocarbon receptor in elevation of CYP1A1 expression and activity in lung cells and tissues by arsenic: an in vitro and in vivo study. Toxicol Sci 2009;107:385-393.
52. Chao HR, Tsou TC, Li LA, et al. Arsenic inhibits induction of cytochrome P450 1A1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin in human hepatoma cells. J Hazard Mater 2006;137:716-722.
53. Kann S, Huang MY, Estes C, et al. Arsenite-induced aryl hydrocarbon receptor nuclear translocation results in additive induction of phase I genes and synergistic induction of phase II genes. Mol Pharmacol 2005;68:336-346. (Pubitemid 41058297)
54. Elbekai RH, El-Kadi AO. Modulation of aryl hydrocarbon receptor-regulated gene expression by arsenite, cadmium, and chromium. Toxicology 2004;202:249-269. (Pubitemid 39165399)
55. Maier A, Dalton TP, Puga A. Disruption of dioxin-inducible phase I and phase II gene expression patterns by cadmium, chromium, and arsenic. Mol Carcinog 2000;28:225-235.
56. Hansen LA, Sigman CC, Andreola F, et al. Retinoids in chemo-prevention and dif erentiation therapy. Carcinogenesis 2000;21: 1271-1279. (Pubitemid 30455984)
57. Chelbi-Alix MK, Bobe P, Benoit G, et al. Arsenic enhances the activation of Stat1 by interferon gamma leading to synergistic expression of IRF-1. Oncogene 2003;22:9121-9130. (Pubitemid 38067987)
58. Nayak S, Shen M, Bunaciu RP, et al. Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and dif erentiation in PML-RARalpha negative human myeloblastic leukemia cells. Leuk Lymphoma 2010;51:1734-1747.
59. Dolniak B, Katsoulidis E, Carayol N, et al. Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2. J Biol Chem 2008;283:12034-12042.
60. Bailey DN, Briggs JR. Valproic acid binding to human serum and human placenta in vitro. T er Drug Monit 2005;27:375-377. (Pubitemid 40770996)
61. Nau H, Zierer R, Spielmann H, et al. A new model for embryotoxi-city testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrations. Life Sci 1981;29: 2803-2814.
62. Jung BH, Kim BJ, Lee MS, et al. Dose-dependent pharmaco-kinetics of toxic metabolites is not related to increased toxicity follow ing high-dose valproic acid in rats. J Appl Toxicol 2011;30: 775-778.
63. Padmanabhan R, Shaf ullah M, Benedict S, et al. effect of maternal exposure to homocystine on sodium valproate-induced neural tube defects in the mouse embryos. Eur J Nutr 2006;45:311-319. (Pubitemid 44386849)
64. Emmanouil-Nikoloussi EN, Foroglou NG, Kerameos-Foroglou CH, et al. effect of valproic acid on fetal and maternal organs in the mouse: a morphological study. Morphologie 2004;88: 41-45.
65. Koch S, Jager-Roman E, Losche G, et al. Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatr 1996;85:739-746. (Pubitemid 26262557)
66. Nau H, Tzimas G, Mondry M, et al. Antiepileptic drugs alter endogenous retinoid concentrations: a possible mechanism of teratogenesis of anticonvulsant therapy. Life Sci 1995;57:53-60.